Generic Striverdi Respimat Availability
Last updated on Apr 10, 2025.
Striverdi Respimat is a brand name of olodaterol, approved by the FDA in the following formulation(s):
STRIVERDI RESPIMAT (olodaterol hydrochloride - spray, metered;inhalation)
-
Manufacturer: BOEHRINGER INGELHEIM
Approval date: July 31, 2014
Strength(s): EQ 0.0025MG BASE/INH [RLD]
Is there a generic version of Striverdi Respimat available?
No. There is currently no therapeutically equivalent version of Striverdi Respimat available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Striverdi Respimat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Patent 7,220,742
Issued: May 22, 2007
Inventor(s): Lustenberger; Philipp et al.
Assignee(s): Boehringer Ingelheim International GmbH (Ingelheim, DE)The present invention relates to enantiomerically pure compounds of general formula 1 ##STR00001## wherein the groups R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X.sup.- may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
Patent expiration dates:
- May 12, 2025✓✓✓
- May 12, 2025
-
Medicaments for the treatment of chronic obstructive pulmonary disease
Patent 7,727,984
Issued: June 1, 2010
Inventor(s): Konetzki; Ingo et al.
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG (Ingelheim, DE)A pharmaceutical composition comprising a compound of formula 1 ##STR00001## wherein: n is 1 or 2; R.sup.1 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.2 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.3 is hydrogen, C.sub.1-C.sub.4-alkyl, OH, halogen, --O--C.sub.1-C.sub.4-alkyl, --O--C.sub.1-C.sub.4-alkylene-COOH, or --O--C.sub.1-C.sub.4-alkylene-CO--O--C.sub.1-C.sub.4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
Patent expiration dates:
- January 19, 2027✓
- January 19, 2027
-
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Patent 8,034,809
Issued: October 11, 2011
Inventor(s): Lustenberger; Philipp et al.
Assignee(s): Boehringer Ingelheim International GmbH (Ingelheim, DE)Enantiomerically pure compounds of general formula 1 ##STR00001## wherein the groups R.sup.1, R.sup.2, R.sup.3, R.sup.4, and X.sup.- may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
Patent expiration dates:
- May 12, 2025✓
- May 12, 2025
More about Striverdi Respimat (olodaterol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: adrenergic bronchodilators
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.